Literature DB >> 18073387

Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression?

Edwin K Silverman1.   

Abstract

The impact of chronic obstructive pulmonary disease (COPD) exacerbations on decline in FEV(1) has been a controversial topic for decades. We will review some of the key studies in this area and discuss potential contributors to inconsistent results of these studies. Dissecting the heterogeneous COPD syndrome into meaningful subtypes and assessing the genetic and environmental influences on COPD-related phenotypes such as exacerbation frequency could clarify the impact of exacerbations on the natural history of COPD.

Entities:  

Mesh：

Year:  2007        PMID： 18073387      PMCID： PMC2647649          DOI： 10.1513/pats.200706-068TH

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN： 1546-3222


  14 in total

1.  Impact of preventing exacerbations on deterioration of health status in COPD.

Authors:  S Spencer; P M A Calverley; P S Burge; P W Jones
Journal:  Eur Respir J       Date:  2004-05       Impact factor: 16.671

2.  The natural history of chronic airflow obstruction.

Authors:  C Fletcher; R Peto
Journal:  Br Med J       Date:  1977-06-25

3.  A long-term follow-up of respiratory symptoms and ventilatory function in a group of working men.

Authors:  P Howard
Journal:  Br J Ind Med       Date:  1970-10

4.  Variables associated with changes in spirometry in patients with obstructive lung diseases.

Authors:  R E Kanner; A D Renzetti; M R Klauber; C B Smith; C A Golden
Journal:  Am J Med       Date:  1979-07       Impact factor: 4.965

5.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Authors:  J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

6.  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

Authors:  R E Kanner; N R Anthonisen; J E Connett
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

7.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Authors:  Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

8.  Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

Authors:  Peter M A Calverley; Sally Spencer; Lisa Willits; P Sherwood Burge; Paul W Jones
Journal:  Chest       Date:  2003-10       Impact factor: 9.410

9.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

10.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.

Authors:  Bartolome R Celli; Claudia G Cote; Jose M Marin; Ciro Casanova; Maria Montes de Oca; Reina A Mendez; Victor Pinto Plata; Howard J Cabral
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245
View more
  15 in total

1.  Chronic obstructive pulmonary disease phenotypes: the future of COPD.

Authors:  MeiLan K Han; Alvar Agusti; Peter M Calverley; Bartolome R Celli; Gerard Criner; Jeffrey L Curtis; Leonardo M Fabbri; Jonathan G Goldin; Paul W Jones; William Macnee; Barry J Make; Klaus F Rabe; Stephen I Rennard; Frank C Sciurba; Edwin K Silverman; Jørgen Vestbo; George R Washko; Emiel F M Wouters; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

2.  Genetic epidemiology of COPD (COPDGene) study design.

Authors:  Elizabeth A Regan; John E Hokanson; James R Murphy; Barry Make; David A Lynch; Terri H Beaty; Douglas Curran-Everett; Edwin K Silverman; James D Crapo
Journal:  COPD       Date:  2010-02       Impact factor: 2.409

3.  Identification of Chronic Obstructive Pulmonary Disease Axes That Predict All-Cause Mortality: The COPDGene Study.

Authors:  Gregory L Kinney; Stephanie A Santorico; Kendra A Young; Michael H Cho; Peter J Castaldi; Raul San José Estépar; James C Ross; Jennifer G Dy; Barry J Make; Elizabeth A Regan; David A Lynch; Douglas C Everett; Sharon M Lutz; Edwin K Silverman; George R Washko; James D Crapo; John E Hokanson
Journal:  Am J Epidemiol       Date:  2018-10-01       Impact factor: 4.897

4.  Using cluster analysis to identify phenotypes and validation of mortality in men with COPD.

Authors:  Chiung-Zuei Chen; Liang-Yi Wang; Chih-Ying Ou; Cheng-Hung Lee; Chien-Chung Lin; Tzuen-Ren Hsiue
Journal:  Lung       Date:  2014-10-07       Impact factor: 2.584

Review 5.  [Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease].

Authors:  Adrian Gillissen; Thomas Glaab; Roland Buhl
Journal:  Med Klin (Munich)       Date:  2009-02-26

6.  Polymorphic variation in surfactant protein B is associated with COPD exacerbations.

Authors:  M G Foreman; D L DeMeo; C P Hersh; V J Carey; V S Fan; J J Reilly; S D Shapiro; E K Silverman
Journal:  Eur Respir J       Date:  2008-06-11       Impact factor: 16.671

7.  Correlation between Telomere Length and Chronic Obstructive Pulmonary Disease-Related Phenotypes: Results from the Chronic Obstructive Pulmonary Disease in Dusty Areas (CODA) Cohort.

Authors:  Da Hye Moon; Jeeyoung Kim; Myoung Nam Lim; So Hyen Bak; Woo Jin Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2021-05-13

8.  A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion.

Authors:  Indranil Chakravorty; Kamaljit Chahal; Gillian Austin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-12-14

Review 9.  New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

Review 10.  The role of bronchodilator treatment in the prevention of exacerbations of COPD.

Authors:  Jadwiga A Wedzicha; Marc Decramer; Terence A R Seemungal
Journal:  Eur Respir J       Date:  2012-07-26       Impact factor: 16.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.